AUTHORS
Gliceida M Galarza Fortuna, MD, Ruitao Liu2, Kian Rahbari3, Xi Qiao, PhD4, Baylee Bryan, PharmD5, Samuel Shewan, PA-C6, Lindsay Maxwell7, Christopher Cahoon, PharmD8, Kelley Julian, PharmD, BCOP9, Rafaella Litvin, MD10, Ghulam Rehman Mohyuddin, MD11, Amandeep Godara, MD12, Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)13, Doug W. Sborov, MD, MS14
AFFILIATIONS
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute, Salt Lake City, Utah, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 Huntsman Cancer Institute, Salt Lake City, Utah, United States
5 Huntsman Cancer Institute, Salt Lake City, Utah, United States
6 Huntsman Cancer Institute, Salt Lake City, Utah, United States
7 Huntsman Cancer Institute, Salt Lake City, Utah, United States
8 Huntsman Cancer Institute, Salt Lake City, Utah, United States
9 Huntsman Cancer Institute, Salt Lake City, Utah, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 Huntsman Cancer Institute, Salt Lake City, Utah, United States
13 Vanderbilt University Medical Center, Nashville, Tennessee, United States
14 Huntsman Cancer Institute, Salt Lake City, Utah, United States
ABSTRACT
Background:
Patients (pts) with multiple myeloma (MM) have an increased risk of developing thromboembolic complications. Although the incidence of thromboembolic events (TE) in newly diagnosed MM (NDMM) has been well studied and defined, the thromboembolic risk in relapsed/refractory MM (RRMM) is less well characterized. We aimed to report the cumulative incidence of thromboembolic events (TE) and characterize regimen-specific risk in pts with RRMM treated with daratumumab(dara)-based regimens enrolled in randomized clinical trials.
Methods:
This retrospective study, carried out under YODA Project #2024-0028, included dara-treated pts in the POLLUX, CASTOR, APOLLO, COLUMBA, and SIRIUS trials. Data was obtained from the Yale University Open Data Access (YODA) Project, which has an agreement with JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. Venous thromboembolism (VTE; deep vein thrombosis, pulmonary embolism, superficial thrombophlebitis) and arterial thromboembolism (ATE; cerebrovascular and other arterial events) were identified from investigator-reported adverse events. Cumulative incidence was estimated in a competing-risk framework with non-TE death as the competing event. Associations between treatment regimen and VTE/ATE were evaluated using Fine-Gray proportional subdistribution hazards models and reported as subdistribution hazard ratios (sHRs), adjusted for age, sex, ECOG performance status, prior lines of therapy, and thromboprophylaxis use. The association between VTE and overall survival (OS) was assessed in a multivariable Cox model with VTE as a time-dependent exposure. As TE was not a prespecified endpoint in any contributing trial, all p-values are exploratory.
Results:
1,299 daratumumab-treated pts were included in the analysis (dara monotherapy 624, 48%; dara-lenalidomide-dex (Dara-Rd) 283, 21.8%; dara-bortezomib-dex (Dara-Vd) 243, 18.7%; dara-pomalidomide-dex (Dara-Pd) 149, 11.5%). Overall, the median age was 64 years (range 30-92), 55% were male, 25.5% had ISS stage III disease, and the median number of prior lines of therapy was 3 (range 1-15). Median follow-up was 40 months overall and ranged from 7.5 months in the COLUMBA trial and 80.1 months in POLLUX.
Pts with and without documented TE had similar age, sex, race, ECOG performance status, ISS stage, and myeloma subtype. Forty-seven pts (3.6%) experienced ≥1 TE, with VTE being more commonly observed (37, 2.8%) compared to ATE (11, 0.8%). Median time to first TE was 5.3 months (range 0.2-64.5). At 6 months, the cumulative incidence of any TE was 3.90% (95% CI 2.07-6.63) with dara-Rd, 2.07% (95% CI 0.78-4.51) with dara-Vd, 1.61% (95% CI 0.76-3.03) with dara-monotherapy, and 0.67% (95% CI 0.06-3.41) with dara-Pd. In pts with longer follow-up, the 24-months cumulative incidence of TE was 6.04% with dara-Rd (95% CI 3.66-9.25), and 2.91% with dara-Vd (95% CI 1.29-5.63). In multivariable analysis, dara-Rd was associated with a higher risk of TE compared to dara-monotherapy (sHR 3.74, 95% CI 1.02-13.68; p<0.05); no other regimen or baseline characteristic was significantly associated with TE. This was driven by VTE (sHR 5.39, 95% CI 1.05-27.77; p<0.05), with no significant ATE association.
Thromboprophylaxis was used in 649 pts (50%). The most commonly used regimen was aspirin (38.4%), followed by enoxaparin (14.4%). DOAC prophylaxis (ppx) was utilized in 6.7% of pts. Ppx use varied greatly by regimen (81.3% dara-Rd, 76.5% dara-Pd, 36.2% dara-Vd, 34.8% dara-monotherapy). Thromboprophylaxis use was associated with a lower risk of death (HR 0.78, 95% CI 0.65-0.95; p<0.05). VTE modeled as a time-dependent exposure was not associated with OS (HR 1.09, 95% CI 0.58-2.02; p=0.79).
Conclusion:
In the largest currently available pooled randomized dataset assessing thromboembolic risk in RRMM, thromboembolic risk was regimen dependent. The highest TE rate was observed in pts treated with a lenalidomide containing regimen, 3.9% and 6.0% at 6-months and 24-months, respectively. This incidence was drastically lower than the previously described 18%-19% in a cohort of NDMM pts treated with lenalidomide-based therapy in the MAIA trial (Rosqvist et al. Blood 2023). TE rate with pomalidomide was numerically lower, 0.6%, suggesting that this may not be a class effect. While TE in the RR setting is less frequent than in NDMM, it remains a clinically relevant issue, especially in lenalidomide-treated pts. Our results suggest that risk-adapted VTE ppx is indicated in this population.
DISCLOSURES
Gliceida M Galarza Fortuna, MD: No relevant conflicts of interest to declare.